| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Letters to the Editor |
Università degli Studi di Parma Parma, Italy L. E. Braverman University of Massachusetts Worcester, MA 01655
The observations made by Çelik et al. related to our
paper on "Increased Serum Concentrations of Interleukin-6 (IL-6) and
Soluble IL-6 Receptor (sIL-6R) in Patients with Graves Disease" (1)
are perhaps based on misinterpretation of some of the data presented.
The group of newly diagnosed hyperthyroid Graves disease (GD)
patients consisted of 31 patients who were tested before antithyroid
treatment (MMI) and were followed until they became euthyroid, within
312 months, at which time thyroid function tests and serum
IL-6/sIL-6R values were reassessed. This group differs from groups of
12 and 19 patients who were restudied at 12 months of therapy and who
were in remission or who had relapsed, respectively. Thus, we do not
believe that the statistical analysis applied, i.e. the
Wilcoxon signed rank test, would result in a type II error because the
groups compared are of sufficiently large size. In addition, while
serum concentrations of sIL-6R declined from 940 to 726 pmol/L after
MMI, those of IL-6 did not. Although the assay employed measured both
free IL-6 and IL-6 bound to the soluble receptor, the molar ratio of
sIL-6R/IL-6 in the circulation is about 10,000:1. It would seem
plausible that the observed changes in sIL-6R concentrations did not
bear a relationship with those of IL-6. In interpreting the lack of
association of either IL-6 or sIL-6R secretion with remission or
relapse of GD, measurement of TSH receptor autoantibody activity would
have been helpful. We found the data of Çelik et al.
on the increased secretion of TNF-
in autoimmune hyperthyroidism of
interest (2). On the other hand, we believe that the IL-6/sIL-6R system
cannot be ruled out as marker of thyroid autoimmunity. We have recently
presented evidence that, in euthyroid GD patients, serum IL-6
concentrations are significantly increased in the serum of those
patients with circulating anti-thyroid peroxidase (TPO) antibodies and
ophthalmopathy during the active inflammatory phase (3). The
understanding of the role of this cytokine in autoimmunity certainly
deserves further study.
Footnotes
1 Address correspondence to: Dr. Lewis E. Braverman, Division of Endocrinology
and Metabolism, University of Massachusetts Medical Center, Worcester,
Massachusetts 01655. ![]()
Received December 30, 1996.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |